Attached files
| file | filename |
|---|---|
| EX-32.2 - EXHIBIT 32.2 - Moleculin Biotech, Inc. | a2018q1ex322.htm |
| EX-31.2 - EXHIBIT 31.2 - Moleculin Biotech, Inc. | a2018q1ex312.htm |
| EX-31.1 - EXHIBIT 31.1 - Moleculin Biotech, Inc. | a2018q1ex311.htm |
| EX-10.2 - EXHIBIT 10.2 - Moleculin Biotech, Inc. | exh102licensemda18-010fina.htm |
| EX-10.1 - EXHIBIT 10.1 - Moleculin Biotech, Inc. | exh101leaseagreement5300me.htm |
| 10-Q - 10-Q - Moleculin Biotech, Inc. | a2018q110q.htm |
Exhibit 32.1
CERTIFICATION PURSUANT TO
18 U.S.C. SECTION 1350,
AS ADOPTED PURSUANT TO
SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002
In connection with the Quarterly Report on Form 10-Q for the quarter ended March 31, 2018 of Moleculin Biotech, Inc. (the “Company”) as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I, Walter Klemp, Chief Executive Officer of the Company, hereby certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that:
• | The Report fully complies with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934 (15 U.S.C 78m or 78o(d)); and |
• | The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company. |
Date: May 14, 2018
By: /s/ Walter V. Klemp |
Walter Klemp |
Chief Executive Officer |
(Principal Executive Officer) |
A signed original of this written statement required by Section 906 has been provided to Moleculin Biotech, Inc. and will be retained by Moleculin Biotech, Inc. and furnished to the Securities and Exchange Commission or its staff upon request.